Alleged Prescription Med. Bottling Error Sparks Class Action Against International Laboratories, Quality Packaging Specialists
Last Updated on January 16, 2019
Johnson v. International Laboratories, Llc et al
Filed: January 10, 2019 ◆§ 7:19cv4
Two companies face a class action after bottles of generic Plavix, a cardiovascular drug, were allegedly mistakenly filled with generic Zocor, an anti-cholesterol drug.
Kentucky
International Laboratories and Quality Packaging Specialists International are the defendants in a proposed class action focused on an alleged prescription medication bottling error.
The plaintiff states in the 11-page complaint that she was prescribed generic Plavix (Clopidogrel) in 2010 to address her risk of cardiovascular conditions. On January 10, 2018, the lawsuit says, the FDA announced a recall initiated by International Laboratories that affected 218,772 bottles of mislabeled Clopidogrel. A short time later, the case continues, a letter sent to the plaintiff from the Walmart Pharmacy she frequented that said an error was made when bottles of Clopidogrel were mistakenly filled with generic Zocor and/or FloLipid (Simvastatin), an anti-cholesterol medication.
According to the suit, the plaintiff attempted to get a refund from International Laboratories by calling the phone number included in the recall notice but was denied because she had “already consumed the product” and disposed of the mislabeled pill bottle.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.